Clinical trials: Pulmonary Aspergillosis
Covid19, Aspergillosis
COVID-19 Associated Pulmonary Aspergillosis (CAPA) and Other Invasive Fungal Infections (IFI)
The purpose of this study is to identify the number of individuals with severe CoVID who require ventilator support and who develop serious fungal infections.
- Conditions
- Covid19, Aspergillosis, Fungal Infection
- Trial name
- CAPA IFI (NCT04818853)
- Testing
- Observation to monitor patients for these infections
- Where
- United States
- Volunteers
- 219 people
- Sponsor
- University of Alabama at Birmingham
Pulmonary Aspergillosis
An Open-label Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S Study)
A study to evaluate the safety and tolerability of opelconazole for the prevention of fungal aspergillus infections in the lung in participants who have received a lung transplant.
- Trial name
- NCT05037851
- Testing
- Opelconazole, Standard of Care
- Where
- 19 sites in United States, Canada
- Volunteers
- 102 people
- Sponsor
- Pulmocide Ltd
Pulmonary Tuberculoses, Chronic Pulmonary Aspergillosis
Vitamin D and Immune Response in Pulmonary Tuberculosis With and Without Chronic Pulmonary Aspergillosis
The goal of the study is to determine whether vitamin D levels are associated with cytokine profiles in patients with pulmonary tuberculosis, including those with chronic pulmonary aspergillosis.
- Conditions
- Pulmonary Tuberculoses, Chronic Pulmonary Aspergillosis, Healthy Participants
- Trial name
- NCT07516158
- Where
- Uzbekistan
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan
Asthma
Pharmacokinetic Profile of Voriconazole Inhalation Powder in Adult Subjects With Asthma
This is a Phase 1b, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability, and pharmacokinetic profiles of voriconazole inhalation powder in adult subjects with well-controlled asthma.
- Trial name
- NCT04576325
- Testing
- Voriconazole Inhalation Powder
- Where
- Australia
- Volunteers
- 17 people
- Sponsor
- TFF Pharmaceuticals, Inc.
Respiratory Infection, Invasive Pulmonary Aspergillosis
Early Diagnosis of Invasive Lung Aspergillosis
The last decade has seen a significant increase in secondary Aspergillus infections, not only due to primary hypersensitivity, and immunodeficiency based on oncological diseases and their therapy, but mainly due to a rise in…
- Trial name
- NCT05860387
- Testing
- Next generation improvement of early invasive aspergillosis
- Where
- 7 sites in Czechia
- Volunteers
- 150 people
- Sponsor
- University Hospital Ostrava
Influenza With Pneumonia, Pulmonary Aspergillosis
Prospective Observational Trial of IAPA
A prospective multi-center observational study to assess the incidence of influenza-associated pulmonary aspergillosis (IAPA) in ICU patients and to identify host- and pathogen related risk factors for IAPA in EORTC negative ICU…
- Trial name
- IAPAFLU (NCT04530799)
- Testing
- Identification of biomarkers for IAPA via patient sampling
- Where
- 12 sites in Belgium, France and 1 more
- Volunteers
- 241 people
- Sponsor
- Radboud University Medical Center
Invasive Pulmonary Aspergillosis
Bronchoalveolar Lavage Lateral-Flow Device Test for Invasive Pulmonary Aspergillosis: a Multicenter Study
Background Invasive pulmonary aspergillosis (IPA) remains an important cause of morbidity and mortality among patients with hemato-oncological malignancies.
- Trial name
- NCT02058316
- Testing
- Lateral Flow Device Test
- Where
- 4 sites in Austria, Germany
- Volunteers
- 350 people
- Sponsor
- Medical University of Graz
Chronic Pulmonary Aspergillosis, Aspergillosis
Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility Study
This study explores the role of treatment with interferon-gamma to improve outcomes in chronic pulmonary aspergillosis (CPA). CPA is a progressive infection caused by the fungus Aspergillus affecting patients with chronic lung…
- Trial name
- INCAS (NCT05653193)
- Testing
- Interferon Gamma-1B 0.1 MG Per 0.5 ML Injection PLUS antifungals as standard of care, Antifungals as standard of care
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Manchester University NHS Foundation Trust
Aspergillosis Pneumonia, Pneumocystis Pneumonia
Non-invasive Diagnosis of Invasive Pulmonary Aspergillosis by Use of Biomarkers in Exhaled Breath Condensate
In this study, a new, non-invasive method for diagnosis of pulmonary aspergillosis (PA) will be tested in a clinical pilot project.
- Trial name
- NIPA (NCT04358419)
- Testing
- Aspergillus specific proteins in exhaled breath condensate (EBC), Pneumocystis jirovecii DNA in exhaled breath condensate (EBC)
- Where
- Denmark
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Inger Lise Gade
Allergic Bronchopulmonary Aspergillosis (ABPA)
Interest of IgE Directed Against Recombinant Antigens of Aspergillus Fumigatus in the Diagnosis of Allergic Bronchopulmonary Aspergillosis (ABPA)
Allergic Bronchopulmonary Aspergillosis is a rare pulmonary disease involving allergic mechanisms, which historically affects patients with asthma or cystic fibrosis only. It is a source of respiratory decompensation.
- Trial name
- BPCO (NCT07055230)
- Where
- France
- Volunteers
- 67 people
- Sponsor
- University Hospital, Rouen
Severe COVID-19
COVID-19 and VA-LRTI: Second Versus First Wave of the Pandemic
Multicenter observational retrospective cohort study aiming at comparing the incidence of ventilator-associated lower respiratory tract infections between COVID-19 patients from the first and the second wave of the pandemic.
- Trial name
- CoVAPid2 (NCT05256511)
- Where
- France
- Sponsor
- University Hospital, Lille
Invasive Candidiasis, Mucocutaneous Candidiasis
Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy and safety of ibrexafungerp (SCY-078) in patients ≥ 18 years of age with a documented fungal disease that has been intolerant or…
- Conditions
- Invasive Candidiasis, Mucocutaneous Candidiasis, Coccidioidomycosis, Histoplasmosis
- Trial name
- FURI (NCT03059992)
- Testing
- Ibrexafungerp
- Where
- 37 sites in United States, Austria and 6 more
- Volunteers
- 233 people
- Sponsor
- Scynexis, Inc.
Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis
Oral Itraconazole Versus Combination of Systemic Glucorticoids and Oral Itraconazole in CPA-ABPA Overlap Syndrome
While ABPA and CPA represent two distinct manifestations of Aspergillus-related lung disease, there is an overlap of investigations that are currently used for the diagnosis of these entities.
- Trial name
- GLITZ (NCT05444946)
- Testing
- Prednisone tablet and Itraconazole, Oral itraconazole
- Where
- 2 sites in India
- Volunteers
- 104 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Cystic Fibrosis, Chit1
Duplication in CHIT1 Gene and the Risk for Aspergillus Lung Disease in CF Patients
Title: Duplication in Chitotriosidase (CHIT1) Gene and the Risk for Aspergillus Lung Disease in CF Patients. Aim: To evaluate the link between CHIT1 duplication in CF patients and the predisposition to ABPA or persistent…
- Trial name
- NCT01572870
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Rambam Health Care Campus
Invasive Fungal Infections
Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds
This is a Phase 2, multicenter study to evaluate APX001 for the treatment of invasive fungal infections caused by Aspergillus spp. or rare molds (eg, Scedosporium spp., Fusarium spp., and Mucorales fungi).
- Trial name
- AEGIS (NCT04240886)
- Testing
- fosmanogepix
- Where
- 15 sites in United States, Belgium and 2 more
- Volunteers
- 21 people
- Sponsor
- Basilea Pharmaceutica
Allergic Bronchopulmonary Aspergilloses
A Study Evaluating Vitamin D in Allergic Bronchopulmonary Aspergillosis Complicating Asthma
Allergic bronchopulmonary aspergillosis (ABPA) is a immunological pulmonary disorder caused by hypersensitive reaction to spores of Aspergillus fumigatus.
- Trial name
- NCT03133299
- Testing
- Glucocorticoids, Vitamin D
- Where
- India
- Volunteers
- 30 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
ABPA, Allergic Bronchopulmonary Aspergillosis
Fungal Status and Prognosis in ABPA
This multicenter bidirectional cohort study aims to investigate the clinical characteristics and prognostic outcomes of patients with allergic bronchopulmonary aspergillosis (ABPA) stratified by fungal microbiological status in…
- Conditions
- ABPA, Allergic Bronchopulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis (ABPA), Colonization
- Trial name
- ABPAFUNGAL (NCT07690345)
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Qianfoshan Hospital
Chronic Pulmonary Aspergillosis, CPA
A Trial to Compare Nebulized Amphotericin B and Nebulized Normal Saline as Maintenance in Patients With Chronic Pulmonary Aspergillosis
The treatment of CPA is with oral itraconazole for 6-12 months. Oral itraconazole results in better clinical outcomes in CPA compared to supportive care.
- Conditions
- Chronic Pulmonary Aspergillosis, CPA, Aspergilloma
- Trial name
- NAB-CPA (NCT06447402)
- Testing
- Normal saline, Amphotericin B deoxycholate
- Where
- India
- Volunteers
- 196 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Invasive Fungal Disease, Lung Transplant Recipients
Assessing Diagnostic Methods for Invasive Fungal Disease in Lung Transplant Recipients
This study aims to assess the diagnostic performance of different tests, including metagenomic next-generation sequencing (mNGS), real-time PCR, galactomannan assay, and lateral-flow device tests, in detecting invasive fungal…
- Conditions
- Invasive Fungal Disease, Lung Transplant Recipients, Invasive Pulmonary Aspergillosis, Pneumocystis Jirovecii Pneumonia
- Trial name
- NCT06654076
- Volunteers
- 109 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Chronic Pulmonary Aspergillosis
Six Months Versus 12 Months of Oral Itraconazole Therapy for Management of Treatment naïve Subjects With CPA
The treatment options majorly consist of medical management with at least 6-month long treatment with antifungal drugs - most significantly the azole groups. Itraconazole is the preferred azole for the treatment of CPA.
- Trial name
- NCT03920527
- Testing
- Itraconazole 400 mg
- Where
- India
- Volunteers
- 164 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh